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Noroviruses are the primary cause of epidemic gastroenteritis in humans, and GII.4 strains cause 80% of the overall disease
burden. Surrogate neutralization assays using sera and mouse monoclonal antibodies (MAbs) suggest that antigenic variation
maintains GII.4 persistence in the face of herd immunity, as the emergence of new pandemic strains is accompanied by newly
evolved neutralization epitopes. To potentially identify specific blockade epitopes that are likely neutralizing and evolving be-
tween pandemic strains, mice were hyperimmunized with GII.4-2002 virus-like particles (VLPs) and the resulting MAbs were
characterized by biochemical and immunologic assays. All of the MAbs but one recognized GII.4 VLPs representing strains cir-
culating from 1987 to 2009. One MAb weakly recognized GII.4-1987 and -1997 while strongly interacting with 2002 VLPs. This
antibody was highly selective and effective at blocking only GII.4-2002-ligand binding. Using bioinformatic analyses, we pre-
dicted an evolving GII.4 surface epitope composed of amino acids 407, 412, and 413 and subsequently built mutant VLPs to test
the impact of the epitope on MAb binding and blockade potential. Replacement of the 2002 epitope with the epitopes found in
1987 or 2006 strains either reduced or ablated enzyme immunoassay recognition by the GII.4-2002-specific blockade MAb. These
data identify a novel, evolving blockade epitope that may be associated with protective immunity, providing further support for
the hypotheses that GII.4 norovirus evolution results in antigenic variation that allows the virus to escape from protective herd
immunity, resulting in new epidemic strains.
Noroviruses (NoVs) are the leading cause of severe viral gas-troenteritis and are responsible for 50% of all acute gastroen-
teritis outbreaks in the United States and Europe (3). Although the
severity of disease is usually moderate, lasting 1 to 3 days, infection
can be especially virulent in young children, the elderly, and the
immunocompromised (2, 18, 21, 22, 24, 35, 40). It is estimated
that 200,000 people die each year from NoV infections, primarily
children in the developing world (36). An effective vaccine would
be particularly advantageous for young and aged populations,
military personnel, food handlers, child and health care providers,
cruise ship passengers, and citizens in the developing world. A
central obstacle that blocks NoV vaccine development is the lack
of understanding of the extensive antigenic diversity between the
large number of NoV strains and the complex interrelationships
between host protective immunity and virus antigenic heteroge-
neity.
NoVs are grouped by the major capsid protein amino acid
sequence. Viruses with less than 14.3% difference are classified as
belonging to the same strain, those with 14.3 to 43.8% difference
are classified as having the same genotype, and those with 45 to
61.4% difference are classified as belonging to the same genogroup
(49). Currently, NoVs are grouped into five genogroups (GI to
GV). Viruses of GI and GII are responsible for most human infec-
tions. GI and GII are further subdivided into 8 and 21 different
genotypes, respectively (3, 49). Over the past 2 decades, the ma-
jority of NoV outbreaks have been caused by strains within the
GII.4 genotype. Between 1995 and 2006, four major NoV pan-
demics associated with evolving GII.4 strains have been docu-
mented based on molecular and clinical disease occurrences. Dur-
ing the mid-1990s (34), strain US95/96 was responsible for 55%
of the NoV outbreaks in the United States and 85% of the out-
breaks in the Netherlands (46). In 2002, the US95/96 strain was
replaced by the Farmington Hills strain (47), which was associated
with 80% of the NoV outbreaks (19) in the United States. In
2004, the Hunter GII.4 variant was detected in Australia, Europe,
and Asia (8, 25, 37). This strain was subsequently replaced in 2006
by two new cocirculating GII.4 variants in the United States and
Europe, Laurens (2006a) and Minerva (2006b) (2, 25, 42). In
2009, a new GII.4 variant emerged (GII.4 New Orleans), causing
the majority of outbreaks in the United States, while the Minerva
(2006b) strain also continues to circulate (3).
NoVs are 38-nm icosahedral viruses with an 7.5-kb single-
stranded, positive-sense RNA genome that encodes three large
open reading frames (ORFs). ORF1 encodes the replicase poly-
protein, while ORF2 and ORF3 encode the major and minor cap-
sid proteins, respectively. Expression of the major capsid protein
(ORF2) in baculovirus (23) and Venezuelan equine encephalitis
(VEE) virus (4) results in the formation of virus-like particles
(VLPs) composed of 180 copies of the monomeric protein (38).
The monomer is structurally divided into the shell domain (S),
which forms the core of the particle, and the protruding domain
(P) that extends away from the core. The P domain is further
subdivided into the P1 subdomain (residues 226 to 278 and 406 to
520) and the P2 subdomain (residues 279 to 405) (38). P2 repre-
sents the most exposed polypeptide on the surface of the viral
particle and determines its interactions with potential neutralizing
antibodies and with histo-blood group antigens (HBGAs) (10, 12,
28, 29, 32). The P2 domain of the major capsid protein of GII.4
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strains is evolving rapidly, resulting in new epidemic strains with
altered ligand binding properties and antigenicity (1, 5, 7, 15, 29,
41, 43).
To further study GII.4 antigenic variation, we prepared panels
of both time-ordered GII.4 VLPs and mouse monoclonal anti-
bodies (MAbs) to compare epitopes between VLPs that represent
various stages of NoV evolution. VLPs were constructed repre-
senting each of the pandemic strains (GII.4-1997 [US95/96],
-2002 [Farmington Hills], -2004 [Hunter], and -2006 [Minerva]),
an ancestral strain that circulated prior to the first pandemic out-
break (GII.4-1987), a strain circulating during the brief period
between the 2004 and 2006 pandemic strains (GII.4-2005), and a
newly emergent GII.4 New Orleans strain (GII.4-2009). The lack
of cell culture or small-animal models for NoV cultivation has
restricted the study of neutralization antibodies and epitopes to in
vitro assays that measure the ability of an antibody to “block“ the
binding of a VLP to an HBGA ligand. This in vitro assay has proven
to be highly sensitive, as it differentiates between NoV strains too
similar to be distinguished by enzyme immunoassay (EIA). The
clinical relevance of the blockade assay, as a surrogate neutraliza-
tion assay, has been confirmed in both infected chimpanzees (6)
and Norwalk virus-infected humans (39).
Using EIAs and a surrogate neutralization assay based on VLP-
HBGA interactions, GII.4-1987 and -1997 were antigenically in-
distinguishable from each other as measured by human NoV out-
break sera, VLP-immunized mouse sera, and mouse MAbs (9, 28,
29). The VLPs of strains circulating post-2002 had significantly
less reactivity with sera directed against earlier strain VLPs and
minimal reactivity to mouse MAbs directed against GII.4-1987.
Conversely, selected mouse MAbs generated against GII.4-2006
reacted only with VLPs that circulated from 2002 or later. These
data suggested that the pandemic GII.4-2002 was an important
antigenic hub, while it retained important antigenic features
(blockade epitopes) that characterized the first GII.4 pandemic
strain, GII.4-1997, it also had new antigenic features (blockade
epitopes) that were retained in the 2006 pandemic strain, GII.4-
2006. No blockade antibodies were found to be in common be-
tween GII.4-1987 and GII.4-2006.
To further investigate the complex antigenic profile of the pan-
demic GII.4-2002 strain, relative to other GII.4 outbreak strains,
we created a panel of mouse MAbs directed against GII.4-2002
and compared the reactivity of these MAbs to that of a panel of
time-ordered GII.4 VLPs using EIAs and surrogate neutralization
assays. Combining these empirical data with bioinformatic anal-
yses, a GII.4-2002-specific neutralizing epitope was predicted and
genetic approaches were used to construct mutant VLPs with chi-
meric epitopes. EIA and blockade assays were then used to test the
mutant VLPs to confirm the unique GII.4-2002 blockade epitope.
These data further support the hypothesis that GII.4 NoV evolu-
tion results in antigenic variation of “neutralizing” epitopes de-
fined by antibody blockade assays and thus confirms that protec-
tive herd immunity is a driving force in NoV evolution.
MATERIALS AND METHODS
VLPs. A diverse panel of VLPs representing GI and GII NoV strains and
epitope E mutants was assembled. Briefly, for all constructs except GII.4
New Orleans, ORF2 constructs were inserted directly into the VEE virus
replicon vector for the production of virus replicon particles (VRPs), and
VLPs were expressed in VRP-infected BHK cells and purified by velocity
sedimentation in sucrose. New clones were verified as approximately
35-nm particles visualized by negative-staining electron microscopy (4,
30). The GII.4 New Orleans (2009) VLPs were expressed in the baculovi-
rus system and purified by cesium chloride gradient centrifugation. VLP
protein concentrations were determined using the BCA protein assay
(Pierce).
Mouse immunization, hybridoma production, and IgG purifica-
tion. MAbs were produced and purified by the University of North Car-
olina—Chapel Hill Immunology Core (http://mabs.unc.edu). Briefly, to
develop the anti-GII.4-2002 MAbs, Swiss Webster mice were immunized
on days 0, 20, 40, and 80 with 50 g of VLP in PBS plus 50 l GERBU
adjuvant (Fisher Scientific) for a total of 100 l and splenocytes were fused
on day 84. The resulting hybridomas were subcloned by limiting dilution,
isotyped (Roche), and purified by protein G chromatography (GE Health-
care).
EIAs. MAb reactivity was determined by EIA as reported previously
(26, 28). Briefly, plates were coated with 1 g/ml VLP in phosphate-
buffered saline (PBS) before the addition 2 g/ml purified IgG and incu-
bation, followed by anti-mouse–alkaline phosphatase and color develop-
ment with pNPP substrate solution (Sigma Chemicals). Each step was
followed by washing with PBS– 0.05% Tween 20, and all antibodies were
diluted in 5% dry milk in PBS– 0.05% Tween 20. The EIA data shown in
the figures represent the average of at least three replicates, and these data
are representative of similar data from at least two independent trials. We
established these EIAs using the new MAbs and included PBS and geno-
group I VLP-coated wells as negative controls and polyclonal anti-VLP
mouse sera as positive controls. Antibodies were considered positive for
reactivity if the mean optical density, after background subtraction, of the
VLP-coated wells was greater than three times the mean optical density of
the PBS-coated wells. A two-way analysis of variance (ANOVA) with Bon-
ferroni’s multiple-comparison test was used to compare BT50 values of an
antibody with different VLPs. A difference was considered significant if
the P value was 0.05.
HBGA expression in commercial mucins. To characterize the
HBGAs present in commercial pig gastric mucin (PGM) type III (Sigma
Chemicals), mucin was solvated in PBS at 5 mg/ml and used at 10 g/ml
in PBS to coat EIA plates, which were incubated for 4 h at room temper-
ature, and blocked by incubation overnight at 4°C in 5% dry milk in
PBS– 0.05% Tween 20 before the addition of anti-HBGA MAbs for 1 h of
incubation at 37°C. Antibodies to blood group antigen A or B (Ortho
Clinical Diagnostics, Rochester, NY) were used at a 1/20 dilution, and
antibodies to H, Lewis A, Lewis B, Lewis X (Santa Cruz Biotechnology,
Santa Cruz, CA), or Lewis Y (Calbiochem, Gibbstown, NJ) were used at 1
g/ml. Primary antibody incubations were 1 h at 37°C and were followed
by a cocktail of anti-mouse IgM/IgG-horseradish peroxidase (HRP;
Sigma Chemicals/GE Healthcare) for 30 min at 37°C and color develop-
ment with 1-Step Ultra TMB (3,3=,5,5=-tetramethylbenzidine) ELISA
(enzyme-linked immunosorbent assay) HRP substrate solution. Each
step was followed by a washing step (PBS– 0.05% Tween 20), and all of the
antibodies were diluted in 5% dry milk in PBS– 0.05% Tween 20. Samples
were assayed in triplicate. HBGA expression was considered positive if the
mean optical density of coated wells, after background subtraction, was
greater than three times the mean optical density of PBS-coated wells. As
PGM is a crude preparation, the HBGA phenotype of each lot should be
verified.
VLP binding to synthetic carbohydrates. Biotinylated synthetic
HBGAs (Bi-HBGA; Glycotech, Gaithersburg, MD) were bound to Neutri-
avidin-coated plates (Pierce) at 10 g/ml for 1 h prior to the addition of 1
g/ml VLP for 1.5 h. VLP binding was detected with a mouse MAb,
followed by rabbit anti-mouse IgG-HRP and 1-Step Ultra TMB ELISA
HRP substrate (Fisher Scientific). All of the incubations were done at
room temperature. Each step was followed by washing with PBS– 0.05%
Tween 20, and all reagents were diluted in 5% dry milk in PBS– 0.05%
Tween 20. VLP binding to synthetic HBGAs was considered positive if the
mean optical density, after background subtraction (no HBGA coating),
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of HBGA-coated wells was greater than three times the mean optical den-
sity of PBS-coated wells.
VLP binding to PGM. To evaluate VLP binding to PGM, EIA plates
were coated with PGM as described above for HBGA expression of PGM.
VLPs (1 g/ml) were added to the coated plates for 1 h of incubation,
followed by a cocktail of rabbit anti-GI and anti-GII NoV polyclonal sera
and mouse MAb anti-GII.4-2006-G6 (28) for 45 min of incubation. Sub-
sequently, a mixture of anti-rabbit/anti-mouse IgG-HRP was added for 30
min of incubation and color was developed with 1-Step Ultra TMB ELISA
HRP substrate solution. Each step was followed by washing with PBS–
0.05% Tween 20, and all VLPs and antibodies were diluted in 5% dry milk
in PBS– 0.05% Tween 20. Samples were assayed in triplicate. VLP binding
to mucin was considered positive if the mean optical density, after back-
ground subtraction, of mucin-coated wells was greater than three times
the mean optical density of PBS-coated wells.
Synthetic carbohydrate binding blockade. VLP-HBGA binding
blockade experiments were conducted as previously reported by our
group (28, 29), with minor modifications. Synthetic HBGAs were bound
to Neutri-avidin-coated plates at 10 g/ml for 1 h prior to the addition of
MAb-pretreated VLP at 1 g/ml for 1.5 h of incubation. VLP binding was
detected with rabbit anti-NoV antiserum, followed by anti-rabbit-IgG-
HRP and TMB substrate. The percent control binding was defined as the
binding level in the presence of antibody pretreatment compared to the
binding level in the absence of antibody pretreatment multiplied by 100.
The HBGA ligands used were H type 3 for GII.4-1987 and B trimer for
GII.4-1997, -2002, -2005, -2006, and -2009 (9, 29). All of the incubations
were done at room temperature. Each step was followed by washing with
PBS– 0.05% Tween 20, and all of the reagents were diluted in 5% dry milk
in PBS– 0.05% Tween 20. Two criteria were used to designate an antibody
“blockade competent” (28) (i) a positive dose-response relationship be-
tween antibody treatment and mean percent control binding, as indicated
by a negative slope significantly different from zero by linear regression
analysis, and (ii) at least 50% blockade of the VLP-HBGA interaction
within the dilution series tested. The 50% blockade titer (BT50) was de-
fined as the lowest MAb concentration tested that blocked at least 50% of
VLP binding compared to levels determined in the absence of antibody
pretreatment. Samples that did not reach a BT50 by the antibody concen-
tration were assigned a BT50 value equal to 2 the maximum concentra-
tion tested for statistical analysis. Serum samples that blocked 50%
binding at the lowest concentration tested were assigned a BT50 value
equal to 1/2 the minimum concentration tested for statistical analysis
(29). A one-way ANOVA with Bonferroni’s multiple-comparison test was
used to compare the BT50 values of an antibody with different VLPs. A
difference was considered significant if the P value was 0.05.
Mucin binding blockade. VLP-mucin binding blockade experiments
were conducted as described for VLP-mucin binding and synthetic car-
bohydrate binding blockade assays, except that antibody-pretreated VLPs
were used at 0.5 g/ml and incubated with PGM for 1 h. A blockade
antibody was defined as described above.
Western blot analysis. GII.4-2002 VLP was suspended in Laemmli
loading buffer, and 9 g of protein was loaded onto a prep-well 7.5%
SDS-polyacrylamide gel (Bio-Rad, Hercules, CA). After electrophoresis,
proteins were transferred to Immuno-Blot polyvinylidene difluoride
(PVDF) membrane (Bio-Rad) and blocked. Immobilized proteins were
probed with 1 and 5 g/ml MAb. Antibody-reactive protein was visual-
ized with goat anti-mouse IgG-HRP secondary antibody (GE Healthcare)
and the ECL Western blotting detection kit (GE Healthcare). All of the
incubations were done at room temperature. Each step was followed by
washing with PBS– 0.05% Tween 20, and all reagents were diluted in 5%
dry milk in PBS– 0.05% Tween 20.
Structural models of VLP P domains. The amino acid sequences of
GII.4.1987, GII.4.2002, and GII.4.2006 VLPs were individually aligned
with the VA387 P domain sequence using ClustalX 1.86 (14), and the
VA387 P domain dimer X-ray crystal structure (PDB accession no. 2OBT)
(10) was used as a template for generating homology models. Homology
models were generated using the program Modeler available via the Max
Planck Institute Bioinformatics Toolkit (http://toolkit.tuebingen.mpg
.de/). The structural models were analyzed and compared, and figures
were generated using Mac Pymol (Delano Scientific).
RESULTS
Anti-GII.4-2002 MAb reactivity. The capsid genes of the GII.4
NoVs are undergoing epochal evolution resulting in phenotypic
changes at the level of antigenicity and ligand binding affinity (9,
28, 29). Our comprehensive study of GII.4 antigenicity over time,
utilizing mouse MAbs to the ancestral strain GII.4-1987 and a
more contemporary strain, GII.4-2006, illustrated that the pan-
demic strain GII.4-2002 was divergent from both GII.4-1987 and
GII.4-2006 but retained some epitopes of each strain. These find-
ings suggest that GII.4-2002 may be an antigenic switching point
that set the stage for significant GII.4 evolution and antigenic
change. To test this hypothesis, we developed a panel of mouse
MAbs to GII.4-2002 (Table 1) and evaluated MAb reactivity
across a large panel of NoV VLPs (Fig. 1). As observed with the
MAbs directed against other GII.4 VLPs, none of the anti-GII.4-
2002 MAbs recognized any of the GI VLPs tested (data not
shown). Three of the five MAbs (G1, G2, and G3) reacted across
the panel of 1987 to 2009 time-ordered GII.4 VLPs and with ad-
ditional GII VLPs representing GII.1-1971 and GII.2-1976. All
three of these MAbs had similar reactivity patterns to each VLP,
indicating that they may share an epitope. Two MAbs (G4 and G6)
recognized only the time-ordered panel of GII.4 VLPs. Anti-
2002-G4 reactivity was variable between the GII.4 VLPs. Anti-
GII.4-2002-G6 detected only a subset of GII.4 VLPs representing
early strains GII.4-1987, GII.4-1997, and GII.4-2002, the same
pattern identified for antibodies generated against GII.4-1987.
These EIA data suggest that our panel of anti-GII.4-2002 MAbs
recognize at least two different epitopes on GII.4 NoV capsids.
Characterization of a commercially available PGM as a sub-
strate for NoV surrogate neutralization assays. EIAs provide in-
formation on the presence or absence of an epitope on a VLP.
Neutralization assays provide information on the function of an
antibody in protection from infection. In the absence of a cell
culture model, blockade of VLP binding to Bi-HBGAs has been
used extensively as a NoV surrogate neutralization assay (20, 27,
28). However, the high cost, limited availability, and limited di-
versity of commercial synthetic HBGAs have hampered progress
in the field. Robust human NoV VLP binding to PGM has been
reported (44, 45), reflecting the native HBGA milieu in biological
samples. To determine if commercial mucin preparations could
serve as a biochemically semicharacterized HBGA ligand source in
surrogate neutralization assays, we first characterized the HBGA
distribution of semipurified PGM type III using MAbs to H anti-
gen, Lewis A antigen, Lewis B antigen, Lewis X antigen, Lewis Y
antigen, A antigen, and B antigen. In agreement with previous
reports of HBGA distribution in individual animals (11), PGM
TABLE 1 MAbs developed in this study
Clone Species Clone no. Immunogen Isotype
GII.4-2002G1 Mouse 66.72.12.12 GII.4-2002 IgG2b
GII.4-2002G2 Mouse 66.691.7.2 GII.4-2002 IgG2a
GII.4-2002G3 Mouse 66.757.1.7 GII.4-2002 IgG2b
GII.4-2002G4 Mouse 66.71.4.2 GII.4-2002 IgG2b
GII.4-2002G6 Mouse 66.573.13.2 GII.4-2002 IgG1
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was positive for relatively high levels of H and A antigens and more
moderate levels of Lewis Y antigen (Fig. 2A). Lewis A, Lewis B,
Lewis X, and B antigens were not detected (11). These data suggest
that PGM may have broad NoV VLP binding properties because
of abundantly available -1,2-fucose (H antigen) and -1,4-
fucose (Lewis antigen) moieties.
GII.4 VLPs from 1987 to 2002 have all been reported to bind to
at least one of the HBGAs abundant in PGM (29). However, syn-
thetic HBGA binding ligands for GII.4-2004, -2005, and -2009
VLPs have not been reported. Therefore, the carbohydrate bind-
ing profile of these VLPs was determined (Fig. 2B). GII.4-2002
bound to H type 3, Lewis Y, and B trimer (29, 48). Consistent with
our previous report (29), a ligand binding partner for GII.4-2004
VLP was not identified in this assay, perhaps reflecting residue
microvariation occurring within the different GII.4-2004 Hunter
strains used by different laboratories or the difference between
VLP binding compared to P particle binding (29, 48). MAb based
detection reagents identified GII.4-2005 VLP binding to H type 3,
Lewis Y(weakly), A, and B trimer; as reported for GII.4-2005 P
particles (48). Consistent with GII.4-2006 VLP binding profiles,
GII.4-2009 bound preferentially to H type 3, Lewis Y, and B trimer
and modestly to A trimer. These results indicate that the panel of
GII.4 VLPs, except GII.4-2004, bind to the HBGA found in PGM.
To confirm this suggestion, the panel of GII.4 time-ordered
VLPs was tested directly for PGM binding. VLP binding to PGM
was consistent with synthetic HBGA binding profiles. All of the
VLPs tested, except GII.4-2004, bound to H, A, and/or Lewis an-
tigens in the synthetic HBGA assays (Fig. 2B) (9, 29), and all VLPs
tested, except GII.4-2004, bound to PGM (Fig. 2C) at a 1 g/ml
VLP concentration. The HBGA binding characteristics of GII.4-
2004 have been reported as either less robust than other GII.4
strains using P particles (48) or below the limit of detection using
VLPs (Fig. 2B) (29). To determine if GII.4-2004 VLPs were struc-
turally incapable of binding PGM or if they had a relatively weak
ligand binding affinity, the PGM binding assay was repeated with
increasing concentrations of GII.4-2004 VLP and binding was de-
tected with a cocktail of MAbs and polyclonal antibodies. Under
these conditions, dose-dependent binding of GII.4-2004 to PGM
was detected, confirming that GII.4-2004 VLPs do bind mucin
ligand but with lower affinity than other GII.4 VLPs (Fig. 2D).
Threefold more VLP (3 g/ml) than the other GII.4 VLPs (1 g/
ml) was required to detect binding of GII.4-2004 to PGM. The
broad ability of PGMs to bind to NoV VLPs indicates that PGM
could be a suitable ligand for NoV surrogate neutralization assays.
Neutralization potential of anti-GII.4-2002 MAbs. To evalu-
ate the VLP-mucin blockade assay, the blockade phenotype of our
panel of anti-GII.4-2002 MAbs was compared using both the tra-
ditional VLP-synthetic HBGA and VLP-PGM blockade assays.
The ability of the anti-GII.4-2002 MAbs to block the interaction of
GII.4-2002 with Bi-B trimer was determined first. The three anti-
bodies (G1, G2, and G3) with broad reactivity across GII VLPs by
EIA and anti-GII.4-2002-G4 were unable to block homotypic VLP
binding to Bi-B trimer (Fig. 3). Anti-GII.4-2002-G6 did block
homotypic VLP interactions (BT50, 0.08 g/ml) (Fig. 3) but was
unable to block any other GII.4 VLP interaction with synthetic
HBGAs (Fig. 4). In agreement with Bi-HBGA blockade results,
anti-GII.4-2002-G6 efficiently blocked the GII.4-2002 VLP-PGM
interaction (BT50, 0.08 g/ml) (Fig. 5). This blockade was selec-
tive, as the antibody had no effect on the GII.4-1987 or GII.4-1997
VLP interactions with PGM or Bi-HBGA (Fig. 4 and 5), despite
limited EIA reactivity with both VLPs. Anti-GII.4-2002-G6 did
not recognize any VLPs post-2002 by EIA; therefore, no additional
FIG 1 EIA cross-reactivity of anti-GII.4-2002 MAbs to NoV VLPs. Purified MAbs were assayed by EIA for reactivity to GI and GII NoV VLPs. (A) MAbs with
cross-genogroup reactivity. (B) MAbs with cross-genotype reactivity. Bars represent means with standard errors. Positive reactivity was defined as a mean optical
density (OD) at 405 nm 3 time that of the background (dashed line). Asterisks indicate VLPs with reactivity significantly different from that of GII.4-2002.
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VLPs were assessed for blockade. The synthetic HBGA and the
PGM-based surrogate neutralization assays provided similar mea-
sures of the antibody’s ability to block VLP-ligand interaction and
indicate that MAb GII.4-2002-G6 recognizes a GII.4-2002-
specific blockade epitope.
Epitope characterization by Western blot analysis. Initial
epitope characterization was done via Western blot analysis to
determine if the epitopes recognized by the panel of MAbs were
conformational or linear sequences. As expected, MAbs without
VLP-ligand binding blockade activity (GII.4-2002-G1 to -G4) rec-
ognized denatured VLP and the MAb with VLP-ligand binding
blockade activity (GII.4-2002-G6) did not recognize a linear
epitope, as measured by Western blot reactivity (Fig. 6). These
data, combined with EIA data demonstrating broad GII.4 reactiv-
ity of GII.4-2002-G1, -G2, -G3, and -G4, suggest that these anti-
bodies may recognize highly conserved linear epitopes and may be
suitable for diagnostics.
Epitope mapping of anti-GII.4-2002-G6. Previous work has
indicated that blockade epitopes are located in the P2 subdomain
and are likely dependent on the appropriate confirmation (17, 28,
31). Bioinformatic analyses identified five putative epitopes based
upon variation that maps to the P2 subdomain surface of the NoV
capsid (16). Epitope E, composed of surface-exposed residues 407,
412, and 413, is located in the P2 subdomain lateral to the receptor
binding sites on the top of the surface. Because epitope E is located
distal to the other epitopes, encodes significant amino acid change
over time, and varies among 1987, 2002, and 2006; this putative
epitope was selected for further characterization (Fig. 7). Using
the GII.4.1987, GII.4.2002, and GII.4.2006 VLPs and capsid se-
quences as a guide, mutants were engineered that contained chi-
meric combinations of epitope E in the GII.4-1987 and GII.4-2006
wild-type backgrounds (Fig. 8). To test if any of the anti-GII.4-
2002 MAbs interacted with epitope E, exchange mutant VLPs
were constructed (Fig. 8A) and reactivity to anti-GII.4-2002
MAbs was evaluated by EIA. Anti-GII.4-2002-G6 recognized the
ancestral GII.4-1987 VLP but not the contemporary GII.4-2006
VLP by EIA (Fig. 1B). Epitope E of the nonreactive GII.4-2006
VLP was put into the reactive GII.4-1987 backbone, resulting
in VLP GII.4-1987/2006 E. This exchange resulted in complete
loss of GII.4-2002-G6 binding (Fig. 8B). Conversely, when
epitope E of the reactive GII.4-1987 VLP was put into the nonre-
active GII.4-2006 backbone, creating VLP GII.4-2006/1987 E,
binding of MAb GII.4-2002-G6 was gained, although at low levels
near the 3-fold background. To test the impact of amino acid 412
within epitope E, N412 of GII.4-2006 was replaced with T412 of
GII.4-1987, resulting in VLP GII.4-2006/N412T (Fig. 9A). This
amino acid change restored the original 2002 sequence at 407 and
412 and converted a GII.4-2002-G6 nonbinding backbone into a
binding VLP. MAb binding was restored to approximately 87% of
GII.4-2002 levels (Fig. 8B). Consistent with a lack of blockade of
GII.4-1987, epitope E exchange mutations into the 2006 backbone
did not restore the GII.4-2002 blockade phenotype (Fig. 8C and
D). However, exchanging the entire epitope E sequence and
amino acid 412 alone between the reactive and nonreactive GII.4
FIG 2 Characterization of PGM HBGA expression and VLP binding. (A) The HBGA phenotype of commercial PGM was determined by reactivity to a panel of
anti-HBGA MAbs by EIA. Asterisks indicate HBGAs with reactivity significantly different from that of B antigen. (B) Binding to synthetic HBGA found in PGM
of the GII.4 VLPs used in this study and not previously reported. The mean OD is indicated by the line. Whiskers indicate the maximum and minimum values
of replicates. (C) PGM binding ability of NoV VLPs determined by incubating GII.4 and GI.1-1968 VLPs with PGM-coated plates, followed by VLP detection
with an anti-NoV antibody cocktail. (D) GII.4-2004 binds to PGM at higher VLP concentrations. Bars represent means with standard errors. Positive reactivity
was defined as a mean optical density (OD) at 450 nm 3 time that of the background (dashed line).
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backbones allowed us to determine that the E epitope itself is
impacting GII.4-2002-G6 binding and indicates that epitope E is a
potential GII.4-2002 neutralization epitope that varies over time.
These exchanges did not impact the binding of any of the other
anti-GII.4-2002 MAbs (data not shown). Further, VLPs with
changes in other predicted epitopes (16) were tested and did not
show differential reactivity to any of the anti-GII.4-2002 MAbs
(data not shown). These data identify epitope E as a GII.4-2002-
specific blockade epitope.
Modeling of amino acid variation in epitope E over time. Res-
idues 407, 412, and 413 were identified as key amino acids that
were exposed to the surface and that changed frequently over
time, suggesting a role in escape from herd immunity. Because a
potential MAb binding site is larger than three amino acids, resi-
dues within 8 Å of the key amino acids were analyzed to determine
the impact of amino acid replacements at positions 407, 412, and
413 on the local structural neighborhood. This distance was se-
lected because it accounted for most of the residues that were
localized around the E epitope and included all of the residues that
would likely be directly impacted by changes at positions 407, 412,
and 413. By expanding from these three sites to include residues
within 8 Å of those sites, additional variations at positions 355 to
357 were noted (Fig. 9).
Modeling of the predicted impacts of amino acid variation
provides potential mechanistic insights into antibody-VLP inter-
actions at a specific site. Structural modeling predicted that the
primary interaction between GII.4.2002 and MAb GII.4-2002-G6
appears to be amino acid R411, which is invariant among GII.4
strains after 1977 (Fig. 9). Importantly, R411 appears to extend
from the surface of the GII.4-2002 capsid, where it is well posi-
tioned to directly interact with potential MAb binding partners.
R411 has variant rotameric positions that are likely regulated by
S407 and T412 of GII.4-2002, which are uncharged and hydro-
philic and do not directly interact with R411 in the GII.4-2002
homology model (Fig. 9). In contrast, GII.4-1987 epitope E differs
from GII.4-2002 epitope E at two positions, 407 (position 406 in
GII.4-1987) and 355. GII.4-2002 encodes S407 and D355, while
GII.4-1987 encodes N406 and S355. The N-to-S difference at 406/
407 likely alters the rotameric position of R411 in the GII.4.1987
capsid, where N406 likely interacts with R411, preventing the side
chain from extending to the surface and changing the surface to-
pology. This likely reduces the ability of MAb GII.4-2002-G6 to
recognize and bind to the GII.4-1987 VLP. In addition, D355 of
GII.4-2002 is likely an additional residue that is targeted by MAb
GII.4-2002-G6, as the negative charge of this residue extends from
the VLP surface (Fig. 9). Structural studies on cocrystals are
needed to validate these predictions.
FIG 3 Homotypic blockade of GII.4-2002 VLP-B trimer interaction by anti-
GII.4-2002 MAbs. (A) GII.4-2002 VLPs were incubated with increasing con-
centrations of anti-GII.4-2002 MAbs, and the mean percent control binding
was calculated by comparing the amount of VLP bound in the presence of
antibody pretreatment to the amount of VLP bound in the absence of antibody
pretreatment. Error bars represent the standard errors of the means. (B) Mean
MAb concentration (g/ml) needed to block 50% of GII.4-2002 ligand bind-
ing. The mean titer is indicated by the line in the graph. The upper and lower
broken lines in the graph represent the maximum and minimum values. The
asterisk indicates an antibody with a BT50 significantly different from that of
GII.4-2002-G1.
FIG 4 Heterotypic blockade of GII.4 VLP-Bi-HBGA interactions by anti-
GII.4-2002-G6. (A) Increasing concentrations of anti-GII.4-2002-G6 anti-
body were incubated with additional GII.4 VLPs positive for EIA reactivity and
GI.1-1968 as a negative control. The mean percent control binding was calcu-
lated by comparing the amount of VLP bound to Bi-HBGA in the presence of
antibody pretreatment to the amount of VLP bound in the absence of antibody
pretreatment. Error bars represent the standard errors of the means. (B) The
Mean MAb concentration (g/ml) needed to block 50% of GII.4 VLP ligand
binding is indicated by the line in the graph. The upper and lower broken lines
in the graph represent the maximum and minimum values. Asterisks indicate
VLPs with BT50s significantly different from that of GII.4-2002.
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The GII.4-2006 VLP is different from the GII.4-2002 VLP at
five positions, 355 to 357, 412, and 413 (Fig. 9). Interestingly, MAb
GII.4-2002-G6 does not bind to GII.4-2006. This is likely due to at
least three structural modifications. (i) Changing 355DVH357 of
GII.4-2002 to 355SAP357 of GII.4-2006 removes the negative po-
tential of D355 from the VLP surface, which may be a target of
MAb GII.4-2002-G6. (ii) Changing T412 of GII.4-2002 to N412 of
GII.4-2006 likely alters the rotameric position of R411, causing it
to be more buried and therefore less exposed to the surface, where
it can interact with the MAb. (iii) The combination of N412 and
V413, as encoded in the GII.4-2006 VLP, alters the structure of the
putative MAb GII.4-2002-G6 binding site, adding bulky side
chain modifications that are predicted to interfere with antibody
binding (Fig. 9D, E, and F).
DISCUSSION
Understanding the molecular mechanisms governing GII.4 anti-
genic variation is key to designing immunotherapeutics and vac-
cines and developing diagnostic predictions regarding the epi-
demic potential of newly emergent strains. The study of
antigenicity among related GII.4 NoV strains using mouse MAbs
developed against a time-ordered panel of GII.4 VLPs has dem-
onstrated two important findings relative to NoV vaccine design.
First, the major antigenic determinant of GII.4 NoVs (the major
capsid protein) is undergoing antigenic variation over time. Sec-
ond, antibodies can be developed that recognize and potentially
neutralize a broad range of GII.4 strains. Detailed studies utilizing
our panel of time-ordered GII.4 VLPs and mouse MAbs revealed
that antibodies that similarly blocked 1987/1997 VLP-ligand in-
teractions required higher concentrations to block GII.4-2002 li-
gand interactions, suggesting that from a neutralization stand-
point, the pandemic GII.4-2002 strain is antigenically divergent
from the earlier 1987/1997 strains. Divergence at this epitope, and
potentially others, may have provided a herd immunity “escape
hatch” for GII.4-2002, leading to the second NoV pandemic. This
hypothesis is supported by the results of blockade assays utilizing
mouse MAbs derived from GII.4-2006 immunizations. MAbs that
effectively blocked GII.4-2006-ligand binding either required
more MAb for blockade or were completely unable to block GII.4-
2002 and these were universally unable to block GII.4-1987 or
1997-HBGA interactions. These data suggest that the divergence
of neutralizing epitopes as defined by carbohydrate blockade as-
says corresponds to new GII.4 pandemic strain emergence and
that GII.4-2002 represents an antigenic switching point in GII.4
evolution.
These data indicate that a successful NoV vaccine regimen will
FIG 5 Blockade of GII.4 VLP-PGM interactions by GII.4-2002-G6. Increasing
concentrations of anti-GII.4-2002-G6 were incubated with GII.4 VLPs posi-
tive for EIA reactivity, and the mean percent control binding was calculated by
comparing the amount of VLP bound to PGM in the presence of antibody
pretreatment to the amount of VLP bound in the absence of antibody pretreat-
ment. Error bars represent the standard errors of the means. (B) The Mean
MAb concentration (g/ml) needed to block 50% of GII.4 VLP ligand binding
is indicated by the line in the graph. The upper and lower broken lines in the
graph represent the maximum and minimum values. Asterisks indicate VLPs
with BT50s significantly different from that of GII.4-2002.
FIG 6 Detection of GII.4-2002 by Western blot analysis with anti-GII.4-2002
MAbs. GII.4-2002 VLPs were denatured, electrophoresed, and transferred to
PVDF before being probed with 5 g/ml and 1 g/ml MAb. Mouse polyclonal
anti-GII.4-2002 serum was used as a positive control for detection.
FIG 7 Epitope E was defined by variable residues 407, 412, and 413. (A)
Variation in epitope E within GII.4 strains. (B) Epitope E (yellow) and HBGA
binding sites (magenta) mapped onto the P domain dimer of GII.4-2002.
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require periodic sampling to identify future strains for inclusion
in subsequent vaccine formulations. The identification of evolv-
ing GII.4 antigenic epitopes provides targeted sites that may be
useful for surveillance and prediction of new strain emergence.
Therefore, we produced a panel of MAbs to the GII.4-2002 VLP
with the goal of identifying epitopes that are changing over time
within GII.4 genotypes. Surprisingly, unlike MAbs generated to
GII.4-1987 and 2006, anti-GII.4-2002 MAbs demonstrated little
difference in EIA reactivity among the time-ordered panel of GII.4
VLPs. Four out of five MAbs recognized the entire panel of time-
ordered VLPs. For three MAbs, the reactivity extended to other
GII VLPs. The four broadly reactive MAbs detected denatured
capsid protein by Western blot analysis, suggesting that these an-
tibodies recognize linear epitopes that are conserved within the
genotype. These data suggest that these antibodies (anti-GII.4-
2002-G1, -G2, -G3, and -G4) do not recognize neutralizing
epitopes, and although not informative about viral antigenic evo-
lution, they do provide potential diagnostic reagents for detection
of broader groups of NoV strains. These antibody reactivity pat-
terns are reminiscent of those generated by immunizing mice with
P particles (48), as the antibodies react with denatured capsid
protein by Western blot analysis but did not block VLP-ligand
interactions. These data underscore an important complication of
using Western blot analysis to determine the antigenic relatedness
of GII.4 strains. As all of the blockade antibodies we have identi-
fied to date (Fig. 4 to 6) (28) recognize conformational epitopes
and Western blot analysis is restricted to denatured epitope eval-
uation, this technique confounds any rational interpretation of
antigenic relatedness between strains and explains why Western
blot analyses have failed to demonstrate antigenic differences be-
tween GII.4 strains (48).
Anti-GII.4-2002-G6 is the only MAb identified to be specific
for blockade of GII.4-2002. This blockade antibody was also the
only GII.4-2002 MAb that did not cross-react with the entire panel
of time-ordered GII.4 VLPs but instead detected only additional
VLPs GII.4-1987 and GII.4-1997. Using genetic approaches and
chimeric VLPs, we identified epitope E, composed of amino acids
407, 412, and 413; as the binding site for MAb GII.4-2002-G6. Our
findings characterize the first novel blockade epitope specific for
the Farmington Hills pandemic GII.4 strain (GII.4-2002). An in-
teresting feature of epitope E is its location on the surface of the
NoV capsid. Unlike other predicted GII.4 epitopes, this epitope
resides lateral to the HBGA binding site. In contrast to the carbo-
hydrate binding pockets that occur directly on top of the P2 sub-
domain; residues 407, 412, and 413 are positioned on the side of
the P2 subdomain extending away from the surface. However,
expanding the epitope to include all amino acid residues within 8
Å of residues 407, 412, and 413 revealed a second region proximal
FIG 8 Characterization of epitope E, a GII.4-2002-specific potential neutralization epitope. (A) VLPs engineered to contain variations of epitope E were
assembled to test the impact of the epitope and the nonepitope backbone on anti-GII.4-2002-G6 binding and neutralization. (B) Anti-GII.4-2002-G6 EIA
reactivity to epitope E constructs. Asterisks indicate chimeric VLPs with reactivity significantly different from that of the parental VLPs. (C) Blockade of epitope
E constructs binding to PGM by anti-GII.4-2002-G6. (D) The mean MAb concentration (g/ml) needed to block 50% of GII.4 VLP ligand binding is indicated
by the line in the graph. The upper and lower broken lines in the graph represent the maximum and minimum values. Asterisks indicate VLPs with BT50s
significantly different from that of GII.4-2002.
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to these sites that includes residues 355 to 357, which are more
exposed to the top of the P2 subdomain. We hypothesize that
these residues are part of the same epitope as residues 407, 412,
and 413. The inclusion of these residues in an expanded epitope E
suggests that MAb GII.4-2002-G6 blocks the ability of the VLP to
interact with its ligand by direct hindrance of the binding pocket.
Mutants have been designed to determine if amino acid positions
355 to 357 and 407, 412, and 413 make up a single epitope.
Other GII.4 epitopes have been predicted using bioinformatic
methods (16) and mapped using molecular biological approaches
(14a). Allan et al. (1) recently compared the reactivities of five
MAbs against a pre- and post-2002 epidemic GII.4 strain and
identified a conformational epitope(s) composed of residues 294
to 296 and 393 to 395. Interestingly, both of these regions were
previously predicted to be epitopes using bioinformatic methods
(1, 16, 28) and were later verified by molecular analyses (1, 29).
The carbohydrate blockade potential of these antibodies was
never tested, so the role of this site in escape from herd immunity
is uncertain. Unfortunately, none of our VLPs allowed a direct
comparison between the two studies but the finding that residues
393 to 395 were antigenically important supported our previously
published work identifying amino acid 395 as an antigenic deter-
minant in the GII.4-2002 Farmington Hills strain (29).
Blockade of VLP binding to biotinylated synthetic HBGAs has
been used extensively as a NoV surrogate neutralization assay by
our group and more recently by others. The key limitation of this
assay is the commercial availability of biotinylated HBGAs, which
occasionally suffer from inconsistent product availability, variable
quality control, and limited offerings compared to the diversity of
the biological molecules. Human salivary samples are a potential
source of biologically relevant HBGAs, but collection is hampered
by the need for institutional review board approval and donor
collection (26). Further, each human salivary sample contains
variable components in variable quantities/time, depending on an
individual’s genetics and behaviors, making it nearly impossible to
develop a standardized sample pool for the NoV field. To address
these limitations, we devised an antibody-mediated VLP-PGM
blockade assay based on the ability of NoV VLPs to bind to com-
FIG 9 Variation in epitope E alters capsid structure. Epitope E was defined by variable residues 407, 412, and 413 (406, 411, and 412 for GII.4.1987) and all
residues within 8 Å of these sites, as these additional residues are likely to be impacted by the structural differences (driven by the variable sites) that contribute
to MAb recognition differences. GII.4.1987 epitope E (A) differs from GII.4.2002 epitope E (B) at positions 406/407 and 355. The N-to-S difference at 406/407
likely alters the rotameric position of R411 in the GII.4.2002 VLP, allowing it to extend further from the surface. (C) GII.4.1987 (yellow) and GII.4.2002 (blue)
superimposed. Because R411 is more buried in 1987, the MAb likely cannot interact as strongly with this residue in the GII.4.1987 VLP. GII.4-2002 (D) differs
from GII.4-2006 (E) at five positions in the expanded epitope (positions 355 to 357, 412, and 413). (F) Superimposition suggests that R411 of GII.4.2006 (teal)
is buried, and variation at 355 to 357 may alter key interactions involving H357 and D355. Red, differences between epitopes; yellow, key residues. (G)
GII.4-2006/N412T (orange) superimposed upon GII.4.2006. Two potentially important residues are R411, which is more surface exposed in GII.4-2006/N412T,
and T412, which is buried. (H) GII.4-2002 (blue) superimposed on GII.4-2006/N412T (orange). R411 is nearly identical, suggesting that N412T frees the R411
side chain to extend away from the surface, where it likely interacts with the MAb. Resides that regulate R411 make up site 1, and 87% of binding can be recovered
with structural modifications to R411. A second site, site 2, is composed of residues 355 to 357, and particularly D355, which adds negative potential to the second
site.
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mercially available, semipurified PGM (45). By nature, the com-
position of gastric mucin is complex and each lot may require
HBGA phenotyping before use as a substrate, but it is inexpensive
and available in semipurified lots, providing a platform for the
evaluation of VLP-carbohydrate interactions. We used anti-
human HBGA MAbs to phenotype the HBGA content of semipu-
rified PGM. These antibodies confirmed the presence of -1,2-
fucose (H antigen), -1,4-fucose (Lewis antigen), and A antigen
for VLP binding. B antigen was not detected, confirming previous
reports of porcine HBGA expression (11). Clearly, the lack of ex-
pressed B antigen limits the depth of the assay, but it does not limit
the functionality of the assay, as all of the VLPs tested by our group
and others bind to H, Lewis, or A antigen. Previously, binding of
NoV VLPs to HBGAs has been shown to be dependent upon the
valency of the carbohydrate (33). Our PGM binding data support
this observation. VLP binding to PGM is stronger than binding to
synthetic HBGAs, allowing us to use half as much VLP per binding
assay and still maintain robust binding signal/noise ratios. For
example, GII.4-2004 binding to PGM was detected at 3 g/ml but
binding to synthetic HBGA was not detected at 5 g/ml. To estab-
lish the VLP-PGM blockade assay, the blockade potential of anti-
GII.4-2002-G6 was characterized using both the traditional bio-
tinylated HBGAs and the PGM blockade assay. These finding have
been replicated for additional panels of anti-NoV MAbs not raised
against GII.4-2002. The response curves of both assays were sim-
ilar for all of the MAbs and polyclonal sera tested (data not
shown), indicating that PGM provides a blockade assay platform
that is affordable and readily available for use in the increasing
numbers of labs interested in NoV surrogate neutralization assays.
The lack of availability of quality-controlled, diverse, biotinyl-
ated HBGAs not only impacts the ability of the research commu-
nity to access potential neutralization of anti-NoV antibodies, it
also impacts the key assay used to characterize HBGA binding
profiles of NoV strains. Conflicting data on GII.4 ligand binding
patterns produced from different labs has been controversial in
the NoV field. Even though a consensus is forming around the
acknowledgment that altered ligand recognition occurs within the
GII.4 strains over time (29), it is important to also acknowledge
that GII.4 ligand recognition varies by assay as no two labs have
exactly the same set of assay reagents, reagent concentrations, or
conditions. Even within our own set of reagents, we have discov-
ered that the choice of detection antibody can impact ligand bind-
ing results. Utilizing MAbs rather than polyclonal sera for detec-
tion increased the assay sensitivity enough to detect lower levels of
biotinylated-HBGA binding. The enhanced detection was appar-
ent only for lower binding signals, such as GII.4-2002-B trimer
and GII.4-2005-H type 3, -Le Y, -A, and -B trimer interactions.
These refined HBGA binding profile results agree with those pub-
lished by others and emphasize the complexity of the NoV-HBGA
binding assays. A final complicating factor in comparing HBGA
binding data between labs is the microvariation within each strain.
As has been demonstrated repeatedly, one amino acid difference
within the P2 domain can significantly alter VLP-HBGA affinity
(13, 15, 29); therefore, making comparisons between data sets is
misleading without the accompanying P2 subdomain sequence
information.
The data presented here on GII.4-2002-HBGA binding and
antigenicity support our hypothesis that GII.4 NoV strains persist
in human populations by altering their affinity for HBGA ligands
in response to antibody-driven antigenic variations. Both of these
features are mediated by epochal evolution of the major capsid
protein. Use of MAbs and blockade assays allowed us to demon-
strate that the pandemic GII.4-2002 strain is antigenically distinct
from the previous pandemic strain GII.4-1997 and the following
pandemic strain GII.4-2006, indicating that new pandemic strain
emergence is associated with changes in neutralizing epitopes.
Identification of a novel GII.4 blockade epitope provides a target
for monitoring new strain emergence and potential therapeutics.
Finally, the identification of these evolving epitopes will provide
key targets for effective vaccine redesign, allowing the rational
reformulation of existing vaccine components to target newly
emerged contemporary strains over time.
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